Intra-Cellular Therapies Announces Positive Topline Results from Study 403 Evaluating Lumateperone as Monotherapy in Patients with Major Depressive Disorder with Mixed Features and Bipolar Depression with Mixed Features
Lumateperone 42mg was statistically significant on the primary endpoint of symptom reduction on the Montgomery Asberg Depression Rating Scale for each patient population including: -combined major... | March 28, 2023
Juan Sanchez Cameron Radinovic Burns Mcclellan Inc Globenewswire Inc Corporate Communications Exchange Commission
Source: marketscreener.com